Pharma Mar saw the highest growth of 1.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Pharma Mar‘s patent filings and grants. Buy the databook here.
Pharma Mar has been focused on protecting inventions in Australia(AU) with two publications in Q2 2024
The Australia(AU) Patent Office dominates the patent filings with nearly 29% of filings. The Australia(AU), United States(US), Hungary(HU), and Israel(IL) patent Office are among the top ten patent offices where Pharma Mar is filings its patents..
Roche and Johnson & Johnson could be the strongest competitors for Pharma Mar
Patents related to rare diseases and climate change lead Pharma Mar's portfolio
Pharma Mar has the highest number of patents in rare diseases followed by, climate change and nanomedicine. For rare diseases, nearly 60% of patents were filed and no patents were granted in Q2 2024.
Small-cell lung cancer related patents lead Pharma Mar portfolio followed by colorectal tumor, and lung cancer
Pharma Mar has highest number of patents in small-cell lung cancer followed by colorectal tumor, lung cancer, ovarian cancer, and sarcomas.
For comprehensive analysis of Pharma Mar's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.